Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

Elias Jabbour, Nicola Gökbuget, Anjali Advani, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Giovanni Martinelli, Susan O'Brien, Tao Wang, A. Douglas Laird, Erik Vandendries, Alexander Neuhof, Kevin Nguyen, Naveen Dakappagari, Daniel J. DeAngelo, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial'. Together they form a unique fingerprint.

Medicine & Life Sciences